Back to search results

Understanding Genetic Testing After Stem Cell Transplant

This observational study aims to find the best way to perform genetic testing for drug metabolism in people who have received an allogeneic hematopoietic stem cell transplant (HSCT). After an HSCT, your body contains cells from both you and your donor, which can make it tricky to get accurate genetic test results for how your body handles medications. This study will collect samples from you and your donor before and after transplant to determine the most reliable source of your own genetic material for these important tests. This research is for adults aged 18 and older who are receiving or donating an HSCT as part of another clinical trial at the NIH Clinical Center for conditions like leukemia, lymphoma, or other blood cancers. The main goal is to identify the most dependable genetic source for pharmacogenetic testing up to 12 months after your transplant.

Study design
This is an observational study with a planned enrollment of 88 participants. It is not a treatment study but rather focuses on collecting and analyzing samples.
What's involved
You and your donor will provide blood, buccal cells (from inside your cheek), skin, and hair samples before your transplant and for two years afterward.
Compensation
Not stated in the trial record.
Follow-up
Samples will be collected and monitored for two years after your transplant.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06856226

Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant

Recruiting
Not specifiedAges 18+Observational
National Cancer Institute (NCI)
~88 participants
Updated 2026-05-27 on ClinicalTrials.gov
What's tested:Arm 1

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To determine the most reliable host genomic source for pharmacogenetic testing in participants that have received allogeneic hematopoietic stem cell transplant (HSCT)
Measured over Pharmacoscan array will be performed within 1 month pre-BM donation in donors and within 1 month pre-HSCT and 12 months post-HSCT in recipients.

Conditions

Leukemia
Lymphoma
Hematologic Malignancy

Explore related trials

LeukemiaLymphomaMalignant neoplasm of lymphoid, hematopoietic and/or related tissue

NCT06856226

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • National Institutes of Health Clinical Center

    Bethesda, Marylandstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Christopher G Kanakry, M.D. · PRINCIPAL_INVESTIGATOR · National Cancer Institute (NCI)

Who to contact

Amy Vicens, R.N.
[email protected]
(240) 921-4889
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age \>=18 years
Participants must be enrolled on a clinical trial at the NIH Clinical Center (CC) under which they will donate or receive an allogeneic HSCT. The participant and their donor must enroll together to provide a complete set of samples for analysis.
Ability of subject to understand and the willingness to sign a written informed consent document.

Exclusion

Donors are not allowed to enroll without a recipient
Prior allogeneic HSCT
History of psychiatric disorder which may compromise compliance with protocol requirements.
Pregnant and lactating individuals

What this trial measures

  • To determine the most reliable host genomic source for pharmacogenetic testing in participants that have received allogeneic hematopoietic stem cell transplant (HSCT)Pharmacoscan array will be performed within 1 month pre-BM donation in donors and within 1 month pre-HSCT and 12 months post-HSCT in recipients.

    Obtaining genotype for analysis of pharmacogene activity by understanding the degree chimerism in commonly utilized diagnostic samples.